328 related articles for article (PubMed ID: 29385079)
1. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.
Tago T; Toyohara J
Molecules; 2018 Jan; 23(2):. PubMed ID: 29385079
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain.
Seo YJ; Muench L; Reid A; Chen J; Kang Y; Hooker JM; Volkow ND; Fowler JS; Kim SW
Bioorg Med Chem Lett; 2013 Dec; 23(24):6700-5. PubMed ID: 24210501
[TBL] [Abstract][Full Text] [Related]
3. Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases.
Tago T; Sakata M; Kanazawa M; Yamamoto S; Ishii K; Toyohara J
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2193-2203. PubMed ID: 38441662
[TBL] [Abstract][Full Text] [Related]
4. HDAC Inhibitors: Innovative Strategies for Their Design and Applications.
Daśko M; de Pascual-Teresa B; Ortín I; Ramos A
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163980
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.
Chen YA; Lu CH; Ke CC; Chiu SJ; Chang CW; Yang BH; Gelovani JG; Liu RS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445342
[TBL] [Abstract][Full Text] [Related]
6. Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.
Bonomi R; Mukhopadhyay U; Shavrin A; Yeh HH; Majhi A; Dewage SW; Najjar A; Lu X; Cisneros GA; Tong WP; Alauddin MM; Liu RS; Mangner TJ; Turkman N; Gelovani JG
PLoS One; 2015; 10(8):e0133512. PubMed ID: 26244761
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone deacetylases for heart diseases.
Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
[TBL] [Abstract][Full Text] [Related]
9. Human neuronal cells: epigenetic aspects.
Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
[TBL] [Abstract][Full Text] [Related]
10. Imaging HDACs In Vivo: Cross-Validation of the [
Donovan LL; Magnussen JH; Dyssegaard A; Lehel S; Hooker JM; Knudsen GM; Hansen HD
Mol Imaging Biol; 2020 Jun; 22(3):569-577. PubMed ID: 31290052
[TBL] [Abstract][Full Text] [Related]
11. Multiple roles of HDAC inhibition in neurodegenerative conditions.
Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases as targets for the treatment of human neurodegenerative diseases.
D'Mello SR
Drug News Perspect; 2009 Nov; 22(9):513-24. PubMed ID: 20072728
[TBL] [Abstract][Full Text] [Related]
13. PET imaging demonstrates histone deacetylase target engagement and clarifies brain penetrance of known and novel small molecule inhibitors in rat.
Schroeder FA; Wang C; Van de Bittner GC; Neelamegam R; Takakura WR; Karunakaran A; Wey HY; Reis SA; Gale J; Zhang YL; Holson EB; Haggarty SJ; Hooker JM
ACS Chem Neurosci; 2014 Oct; 5(10):1055-62. PubMed ID: 25188794
[TBL] [Abstract][Full Text] [Related]
14. High-Contrast PET Imaging with [
Turkman N; Xu S; Huang CH; Eyermann C; Salino J; Khan P
J Med Chem; 2023 Apr; 66(8):5611-5621. PubMed ID: 37068265
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic application of histone deacetylase inhibitors for stroke.
Lv L; Tang YP; Han X; Wang X; Dong Q
Cent Nerv Syst Agents Med Chem; 2011 Jun; 11(2):138-49. PubMed ID: 21521169
[TBL] [Abstract][Full Text] [Related]
16. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA.
Yeh HH; Tian M; Hinz R; Young D; Shavrin A; Mukhapadhyay U; Flores LG; Balatoni J; Soghomonyan S; Jeong HJ; Pal A; Uthamanthil R; Jackson JN; Nishii R; Mizuma H; Onoe H; Kagawa S; Higashi T; Fukumitsu N; Alauddin M; Tong W; Herholz K; Gelovani JG
Neuroimage; 2013 Jan; 64():630-9. PubMed ID: 22995777
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
Konsoula Z; Barile FA
J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
[TBL] [Abstract][Full Text] [Related]
18. Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration.
Trüe O; Matthias P
Immunol Cell Biol; 2012 Jan; 90(1):78-84. PubMed ID: 22124372
[TBL] [Abstract][Full Text] [Related]
19. Insights into neuroepigenetics through human histone deacetylase PET imaging.
Wey HY; Gilbert TM; Zürcher NR; She A; Bhanot A; Taillon BD; Schroeder FA; Wang C; Haggarty SJ; Hooker JM
Sci Transl Med; 2016 Aug; 8(351):351ra106. PubMed ID: 27510902
[TBL] [Abstract][Full Text] [Related]
20. PET Radioligands for imaging of the PDE10A in human: current status.
Boscutti G; A Rabiner E; Plisson C
Neurosci Lett; 2019 Jan; 691():11-17. PubMed ID: 30099081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
